title: Restenosis after successful ostial stent implantation: the role of statins compared with conventional treatment.
abstract: Despite the introduction of coronary stents and effective anticoagulation regimens, the treatment of ostial lesions is limited by high restenosis rates. Initial results have been published asserting that statin therapy is associated with a significant reduction in restenosis after stent deployment. However, no information is available about the effect of statins after ostial stenting. Between 1993 and 2000, 122 patients required ostial placement of coronary stents at the Royal Brompton Hospital in London, United Kingdom. Statin treatment was continued or begun in 52 patients with a documentated hypercholesterolemia. Follow-up was feasible in 97 patients undergoing successful stent implantation. Restenosis rate was lower in patients receiving statins, but did not differ significantly from the nonstatin group (34.6% as against 42.2%, P = 0.531).
authors.affiliation: Department of Cardiology, HELIOS Klinikum Wuppertal, Heartcenter Wuppertal, University of Witten/Herdecke, Arrenberger Strasse 20, D-42117 Wuppertal, Germany. mhorlitz@wuppertal.helios-kliniken.de
authors.forename: Marc
authors.initials: M
authors.lastname: Horlitz
authors.forename: Fouad R
authors.initials: FR
authors.lastname: Amin
authors.forename: Guido
authors.initials: G
authors.lastname: Boerrigter
authors.forename: Ulrich
authors.initials: U
authors.lastname: Sigwart
authors.forename: Jonathan R
authors.initials: JR
authors.lastname: Clague
mesh_terms: D015906:Angioplasty, Balloon, Coronary / Q000379:methods*; D003324:Coronary Artery Disease / Q000628:therapy*; D023903:Coronary Restenosis / Q000517:prevention & control* / Q000628:therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D015607:Stents; D016896:Treatment Outcome
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors